Overview

Viral Inhibition in Children for Treatment of RSV

Status:
Completed
Trial end date:
2019-04-09
Target enrollment:
Participant gender:
Summary
VICTOR is a randomized, double-blind, placebo-controlled, multicenter, 2-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effect of single and multiple dosing of AK0529 in infants hospitalized with RSV infection.
Phase:
Phase 2
Details
Lead Sponsor:
Ark Biosciences Inc.
Collaborator:
Ark Biosciences Pty Ltd.
Treatments:
Ziresovir